Anika Therapeutics (ANIK) Price & Analysis

Compare

172 Followers

ANIK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.87 - $25.83

Previous CloseN/A

Volume22.29K

Average Volume (3M)107.95K

Market Cap

$124.86M

Enterprise Value$123.79M

Total Cash (Recent Filing)$53.17M

Total Debt (Recent Filing)$24.99M

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Oct 30, 2025

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding14,418,090

10 Day Avg. Volume84,334

30 Day Avg. Volume107,949

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue1.00

Enterprise Value/Gross Profit2.33

Enterprise Value/Ebitda-4.25

Forecast

1Y Price Target

$15.50

Price Target Upside73.38% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Cost ManagementThe company's gross margin exceeded forecasts, suggesting efficient cost management.

Financial PerformanceAnika's adjusted EBITDA was better than expected, indicating a stronger than anticipated financial performance.

Investment OpportunityDespite near-term challenges, recent share price weakness is considered a good entry point for new investors and a great opportunity for current investors to add to positions.

Bears Say

Clinical TrialsThe Hyalofast trial did not meet its primary endpoints, which contributed to a lower price target for Anika's stock.

EBITDA GuidanceThe company's adjusted EBITDA guidance for FY/25 has been reduced for the second consecutive quarter.

Revenue ShortfallAnika generated $26.2 million in revenue, which fell short of the estimated $28.0 million.

Anika Therapeutics News

Anika Therapeutics price target lowered to $15 from $19 at Barrington

Barrington analyst Michael Petusky lowered the firm’s price target on Anika Therapeutics (ANIK) to $15 from $19 and...

2M ago

ANIK

Anika Therapeutics Reports Q2 2025 Financial Results

Anika Therapeutics, Inc. ( ($ANIK) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ANIK

Anika Therapeutics’ Earnings Call: A Mixed Outlook

Anika Therapeutics, Inc. (($ANIK)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

ANIK

Anika Therapeutics Announces Phase III Study Results

Anika Therapeutics ( ($ANIK) ) has shared an announcement. On July 30, 2025, Anika Therapeutics announced the topline...

2M ago

ANIK

Anika Therapeutics reports Q2 adjusted EPS (13c) vs 4c last year

Reports Q2 revenue $28.2M, consensus $27.03M. Cheryl Blanchard, President and CEO of Anika Therapeutics (ANIK), commented: “We continue...

2M ago

ANIK

Anika Therapeutics reaffirms FY25 adjusted EBITDA view of down 3% to up 3%

Anika maintains 2025 revenue ranges by channel as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up...

2M ago

ANIK

Anika updates its 2026-2027 revenue guidance for potential Hyalofast delay

Commercial Channel expected to grow +10% to +20% in 2026 and 2027 as compared to the previous guidance...

2M ago

ANIK

Anika Therapeutics trial of Hyalofast missed co-primary endpoints

Anika Therapeutics (ANIK) announced topline results from its U.S. pivotal clinical trial of Hyalofast. Enrollment for this trial...

2M ago

ANIK

ANIK Earnings this Week: How Will it Perform?

Anika Therapeutics, Inc. (ANIK) is scheduled to report 2nd quarter earnings on 07/30/2025, before the market opens. Regarding...

2M ago

ANIK

Anika Therapeutics Approves Key Proposals at Annual Meeting

Anika Therapeutics ( ($ANIK) ) has provided an announcement. On June 20, 2025, Anika Therapeutics held its Annual...

3M ago

ANIK

Anika Therapeutics selloff provides entry point, says Barrington

Barrington lowered the firm’s price target on Anika Therapeutics (ANIK) to $19 from $20 and keeps an Outperform...

4M ago

ANIK

Anika Therapeutics Reports Mixed Q1 2025 Results

Anika Therapeutics, Inc. ( ($ANIK) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

ANIK

Anika Therapeutics’ Mixed Earnings Call Reveals Challenges and Growth

Anika Therapeutics, Inc. (($ANIK)) has held its Q1 earnings call. Read on for the main highlights of the...

4M ago

ANIK

Morning Movers: Pinterest, Lyft jump following quarterly results

Stock futures are modestly higher, extending gains from earlier in the week as optimism around global trade continues...

4M ago

AGM

ANIK FAQ

What was Anika Therapeutics’s price range in the past 12 months?

Anika Therapeutics lowest stock price was $7.87 and its highest was $25.83 in the past 12 months.

What is Anika Therapeutics’s market cap?

Anika Therapeutics’s market cap is $124.86M.

When is Anika Therapeutics’s upcoming earnings report date?

Anika Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 41 days.

How were Anika Therapeutics’s earnings last quarter?

Anika Therapeutics released its earnings results on Jul 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.133.

Is Anika Therapeutics overvalued?

According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anika Therapeutics pay dividends?

Anika Therapeutics does not currently pay dividends.

What is Anika Therapeutics’s EPS estimate?

Anika Therapeutics’s EPS estimate is -0.21.

How many shares outstanding does Anika Therapeutics have?

Anika Therapeutics has 14,418,090 shares outstanding.

What happened to Anika Therapeutics’s price movement after its last earnings report?

Anika Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -27.419%.

Which hedge fund is a major shareholder of Anika Therapeutics?

Currently, no hedge funds are holding shares in ANIK

Anika Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-22.91%

Trailing 12-Months

Asset Growth

-28.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anika Therapeutics

Anika Therapeutics, Inc. is a global medical technology company focused on developing, manufacturing, and commercializing innovative therapeutic solutions primarily in the fields of orthopedics, pain management, and regenerative medicine. The company specializes in hyaluronic acid (HA) technologies, which are used in products ranging from joint therapies and surgical applications to wound healing and dermal fillers. Anika's core products include viscosupplements for osteoarthritis, as well as other regenerative therapies aimed at improving patient outcomes and enhancing quality of life.

Anika Therapeutics (ANIK) Earnings & Revenues

Historic Earnings Reports

ANIK Company Deck

ANIK Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed outlook. There was strong performance from the Integrity product line and progress with Cingal, but notable challenges with Hyalofast's clinical trial results and a decline in overall revenue and gross margin.View all ANIK earnings summaries

ANIK Stock 12 Month Forecast

Average Price Target

$15.50

▲(73.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","12":"$12","17":"$17","22":"$22","27":"$27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12,17,22,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,9.206153846153846,9.772307692307693,10.338461538461539,10.904615384615385,11.470769230769232,12.036923076923078,12.603076923076923,13.169230769230769,13.735384615384616,14.301538461538462,14.867692307692309,15.433846153846154,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,9.167692307692308,9.695384615384615,10.223076923076924,10.750769230769231,11.278461538461539,11.806153846153848,12.333846153846155,12.861538461538462,13.38923076923077,13.916923076923077,14.444615384615386,14.972307692307693,{"y":15.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.64,9.12923076923077,9.618461538461538,10.107692307692307,10.596923076923078,11.086153846153847,11.575384615384616,12.064615384615385,12.553846153846154,13.043076923076924,13.532307692307693,14.021538461538462,14.510769230769231,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.67,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.49,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >